



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Zabicipril

Cat. No.:	HY-105266
CAS No.:	83059-56-7
Molecular Formula:	C ₂₃ H ₃₂ N ₂ O ₅
Molecular Weight:	416.51
Target:	Angiotensin-converting Enzyme (ACE)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Zabicipril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Zabicipril can be used for the study of blood pressure and peripheral arterial insufficiency ^[1] .								
In Vivo	<p>Zabicipril (0.3, 3 mg/kg; p.o.; daily for 5-7 days) inhibits ACE in rat plasma^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Adult male Sprague-Dawley rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.3, 3 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o.; daily for 5-7 days</td> </tr> <tr> <td>Result:</td> <td>Induced 50% and 65% inhibition of plasma ACE activity in the low- and high-dose group, respectively.</td> </tr> </table>	Animal Model:	Adult male Sprague-Dawley rats ^[1]	Dosage:	0.3, 3 mg/kg	Administration:	P.o.; daily for 5-7 days	Result:	Induced 50% and 65% inhibition of plasma ACE activity in the low- and high-dose group, respectively.
Animal Model:	Adult male Sprague-Dawley rats ^[1]								
Dosage:	0.3, 3 mg/kg								
Administration:	P.o.; daily for 5-7 days								
Result:	Induced 50% and 65% inhibition of plasma ACE activity in the low- and high-dose group, respectively.								

REFERENCES

[1]. Yang HT, Terjung RL. Angiotensin-converting enzyme inhibition increases collateral-dependent muscle blood flow. J Appl Physiol (1985). 1993 Jul;75(1):452-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA